Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of RNF34 polyclonal antibody
| Brand | Abnova |
| Product type | Primary antibodies |
| Host species | Goat |
| Applications | ELISA |
More info about RNF34 polyclonal antibody
| Brand: | Abnova |
| Reference: | PAB7471 |
| Product name: | RNF34 polyclonal antibody |
| Product description: | Goat polyclonal antibody raised against synthetic peptide of RNF34. |
| Gene id: | 80196 |
| Gene name: | RNF34 |
| Gene alias: | FLJ21786|RFI|RIF|RIFF |
| Gene description: | ring finger protein 34 |
| Immunogen: | A synthetic peptide corresponding to human RNF34. |
| Immunogen sequence/protein sequence: | C-RLYKENEENQKSY |
| Protein accession: | NP_919247.1;NP_079402.2 |
| Form: | Liquid |
| Concentration: | 0.5 mg/mL |
| Recommend dilutions: | ELISA (1:64000) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In Tris saline, pH 7.3 (0.5% BSA, 0.02% sodium azide) |
| Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Goat |
| Antigen species / target species: | Human |
| Specificity: | This antibody is expected to recognize both reported isoforms (NP_919247.1; NP_079402.2). |
| Applications: | ELISA |
| Shipping condition: | Dry Ice |
| Publications: | Overexpression of hRFI (human ring finger homologous to inhibitor of apoptosis protein type) inhibits death receptor-mediated apoptosis in colorectal cancer cells.Konishi T, Sasaki S, Watanabe T, Kitayama J, Nagawa H. Mol Cancer Ther. 2005 May;4(5):743-50. |